Press Releases

March 27, 2019
Principal Investigator Mandi Pratt-Chapman, MA has been awarded a $4.125 million cooperative agreement to continue work with the Centers for Disease Control and Prevention (CDC) to provide comprehensive technical assistance for National Comprehensive Cancer Control Program (NCCCP) grantees.
March 18, 2019
The George Washington University (GW) Cancer Center is pleased to announce that accomplished medical oncologist George Kim, MD, has joined the GW Cancer Center. He will serve as the director of the Gastrointestinal Cancers Program at the GW Cancer Center.
March 15, 2019
A team at the GW Cancer Center found that the deubiquitinating enzyme USP15 is a potential biomarker for treatments of breast and pancreatic cancers.
February 26, 2019
A team from the George Washington University (GW) Cancer Center has been approved for a $300,000 funding award through the Eugene Washington PCORI Engagement Awards (Engagement Awards) program, an initiative of the Patient-Centered Outcomes Research Institute (PCORI).
February 22, 2019
The George Washington University (GW) Cancer Center is pleased to announce the expansion of the Cutaneous Oncology Multidisciplinary Program. The program will bring together dermatologists, dermatologic surgeons, medical, surgical and radiation oncologists, and pathologists to provide personalized…
February 13, 2019
A new reversible, drug-free antiplatelet therapy could reduce the risk of blood clots and potentially prevent cancer metastasis, according to a study published today in Science Translational Medicine.
January 28, 2019
WASHINGTON (Jan. 28, 2018) - A team from the George Washington University (GW) Cancer Center has engineered a nanoimmunotherapy that combines the advantages of nanotechnology and immunotherapy to treat cancer.
January 16, 2019
The George Washington University (GW) Cancer Center is pleased to announce that Vishal A. Patel MD, FAAD, FACMS, an accomplished Mohs/Dermatologic surgeon and cutaneous oncologist, has joined the GW Cancer Center. He will serve as the director of the recently established Cutaneous Oncology Program…
October 31, 2018
WASHINGTON (Oct. 31, 2018) - Due to their broad antitumor activity that inhibits the function of microtubules, taxanes are common chemotherapeutic agents utilized for the management of multiple cancer types from breast to prostate.
October 1, 2018
Adam Friedman, MD, is the senior author of a study on the efficacy of nanoparticles in therapies for triple-negative breast cancer.